Bicycle Therapeutics plc (NASDAQ:BCYC) Given Consensus Recommendation of “Moderate Buy” by Analysts

Bicycle Therapeutics plc (NASDAQ:BCYC) has earned an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $33.25.

A number of equities analysts have commented on BCYC shares. HC Wainwright reiterated a “buy” rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a report on Monday, January 13th. JMP Securities reduced their price objective on shares of Bicycle Therapeutics from $32.00 to $26.00 and set a “market outperform” rating for the company in a research note on Wednesday, December 18th. Royal Bank of Canada reissued an “outperform” rating and set a $35.00 target price on shares of Bicycle Therapeutics in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a “buy” rating and issued a $32.00 price target on shares of Bicycle Therapeutics in a report on Monday, January 13th. Finally, Stephens reiterated an “equal weight” rating and set a $15.00 price objective on shares of Bicycle Therapeutics in a report on Wednesday, January 22nd.

Insider Activity

In other Bicycle Therapeutics news, Director Bros. Advisors Lp Baker acquired 985,397 shares of the firm’s stock in a transaction on Friday, December 13th. The stock was acquired at an average cost of $13.76 per share, for a total transaction of $13,559,062.72. Following the purchase, the director now owns 9,537,643 shares in the company, valued at approximately $131,237,967.68. The trade was a 11.52 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CAO Travis Alvin Thompson sold 2,686 shares of the company’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $15.00, for a total transaction of $40,290.00. Following the completion of the sale, the chief accounting officer now directly owns 32,146 shares in the company, valued at $482,190. This trade represents a 7.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,677 shares of company stock valued at $392,413 over the last ninety days. 8.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. FMR LLC acquired a new stake in Bicycle Therapeutics during the 3rd quarter worth about $3,406,000. The Manufacturers Life Insurance Company grew its holdings in Bicycle Therapeutics by 33.2% during the third quarter. The Manufacturers Life Insurance Company now owns 129,705 shares of the company’s stock worth $2,935,000 after acquiring an additional 32,313 shares during the period. Principal Financial Group Inc. purchased a new position in Bicycle Therapeutics during the third quarter valued at approximately $10,028,000. State Street Corp raised its position in Bicycle Therapeutics by 233.5% during the third quarter. State Street Corp now owns 86,271 shares of the company’s stock valued at $1,952,000 after acquiring an additional 60,399 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in Bicycle Therapeutics by 35.7% in the third quarter. Jane Street Group LLC now owns 20,180 shares of the company’s stock valued at $457,000 after acquiring an additional 5,310 shares during the period. 86.15% of the stock is currently owned by institutional investors and hedge funds.

Bicycle Therapeutics Trading Down 2.8 %

BCYC opened at $11.84 on Tuesday. The firm has a market cap of $817.50 million, a price-to-earnings ratio of -3.60 and a beta of 0.93. Bicycle Therapeutics has a 12 month low of $11.77 and a 12 month high of $28.67. The stock has a fifty day moving average price of $14.89 and a 200-day moving average price of $20.43.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.